Let’s Magnify Our Efforts
to Treat Dry Age-Related
Macular Degeneration.

Let’s Magnify Our Efforts to Treat Age-Related Dry Macular Degeneration.

About the Magnify Study

About the Magnify Study

The Magnify Study is evaluating the safety and efficacy of an investigational drug, an oral pill called CT1812, as a treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

The Magnify Study is evaluating the safety and efficacy of an investigational drug, an oral pill called CT1812, as a treatment for geographic atrophy (GA) secondary to dry, age-related macular degeneration (AMD).

Learn More

do you
qualify?

do you qualify?

You may be eligible to participate in the Magnify Study if you are 50 years or older and have been diagnosed with GA secondary to dry AMD. Additional study eligibility requirements apply.

You may be eligible to participate in the Magnify Study if you are 50 years or older and have been diagnosed with GA secondary to dry AMD. Additional study eligibility requirements apply.

Do You Qualify?

STUDY
LOCATIONS

STUDY LOCATIONS

The Magnify Study is taking place at several clinical sites in the United States. Click here to find a study site near you.

The Magnify Study is taking place at several clinical sites in the United States. Click here to find a study site near you.
Study Locations

About the Magnify Study

Cognition Therapeutics is evaluating an investigational drug called CT1812 in patients with dry AMD. The purpose of this study is to determine if the drug is safe and effective, and to see how well patients tolerate it.

The drug is taken once each day, by mouth, and the study doctor will meet with you regularly to see how you are doing. Currently, this drug is not yet approved by the Food and Drug Administration (FDA).

Up to 246 participants will be enrolled in the Magnify Study. Participation in the Magnify Study is voluntary and a person in the study may stop participation at any time.

The Magnify Study is evaluating the investigational drug, CT1812, in adults over 50 who have GA secondary to dry AMD.

The purpose of this study is to learn about the safety of CT1812 and how well patients tolerate a once-a-day, oral dose of CT1812. The study will also evaluate how well CT1812 will treat GA secondary to dry AMD.

Up to 246 participants will be enrolled in the Magnify Study.

About the Magnify Study

The Magnify Study is evaluating the investigational drug, CT1812, in adults over 50 who have GA secondary to dry AMD.

The purpose of this study is to learn about the safety of CT1812 and how well patients tolerate a once-a-day, oral dose of CT1812. The study will also evaluate how well CT1812 will treat GA secondary to dry AMD.

Up to 246 participants will be enrolled in the Magnify Study.

Cognition Therapeutics is evaluating an investigational drug called CT1812 in patients with dry AMD. The purpose of this study is to determine if the drug is safe and effective, and to see how well patients tolerate it.

The drug is taken once each day, by mouth, and the study doctor will meet with you regularly to see how you are doing. Currently, this drug is not yet approved by the Food and Drug Administration (FDA).

Up to 246 participants will be enrolled in the Magnify Study. Participation in the Magnify Study is voluntary and a person in the study may stop participation at any time.

Participants will be randomly assigned to 1 of the 2 groups in this study:

Group 1 :

Will take 200 mg of CT1812
(2 capsules) once daily.

Group 2 :

Will take the placebo
(2 capsules) once daily.

A placebo is a capsule that looks identical to the investigational drug but does not contain any active ingredient.
Neither you nor the study doctor will know whether you are receiving CT1812 or placebo.

Participants will be randomly assigned to 1 of the 2 groups in this study:

Group 1 :

Will take 200 mg of CT1812
(2 capsules) once daily.

Group 2 :

Will take the placebo
(2 capsules) once daily.

A placebo is a capsule that looks identical to the investigational drug but does not contain any active ingredient.
Neither you nor the study doctor will know whether you are receiving CT1812 or placebo.

STUDY DURATION

The total duration of participation in the study is about two years. Each participant will take part in a Screening Visit of up to 60 days prior to receiving the first dose of the investigational drug. This is followed by a double-masked study* of 24 months, and a follow-up visit within 1 month after receiving the last dose.

*A double-masked study is a type of clinical trial in which neither the participants nor the researchers know which treatment participants are receiving until the clinical trial is over.

ABOUT THE INVESTIGATIONAL DRUG

The investigational drug, CT1812, is being studied for the treatment of GA secondary to dry AMD. CT1812 comes in the form of two capsules taken every morning by mouth, with or without food. This investigational drug will be compared to a placebo. In this study, participants have a 50-50 chance of receiving the investigational drug, CT1812 versus the placebo.

To date, CT1812 has been well-tolerated in other clinical trials. Mild and transient elevations of liver enzymes have been observed without any other indications of liver injury. However, since CT1812 has not yet been tested in people as a dry AMD treatment, its potential risks and benefits in the Magnify Study are unknown.

STUDY DURATION

The total duration of participation in the study is about two years. Each participant will take part in a Screening Visit of up to 60 days prior to receiving the first dose of the investigational drug. This is followed by a double-masked study* of 24 months, and a follow-up visit within 1 month after receiving the last dose.

*A double-masked study is a type of clinical trial in which neither the participants nor the researchers know which treatment participants are receiving until the clinical trial is over.

ABOUT THE INVESTIGATIONAL DRUG

The investigational drug, CT1812, is being studied for the treatment of GA secondary to dry AMD. CT1812 comes in the form of two capsules taken every morning by mouth, with or without food. This investigational drug will be compared to a placebo. In this study, participants have a 50-50 chance of receiving the investigational drug, CT1812 versus the placebo.

To date, CT1812 has been well-tolerated in other clinical trials. Mild and transient elevations of liver enzymes have been observed without any other indications of liver injury. However, since CT1812 has not yet been tested in people as a dry AMD treatment, its potential risks and benefits in the Magnify Study are unknown.

What to Expect During the Magnify Study

Informed Consent

To participate in the Magnify Study, participants will be asked to read and sign an Informed Consent Form (ICF). The form explains:

  • The purpose of the study
  • Required study visits and procedures
  • Potential risks and benefits of participation
  • Confidentiality
  • How participant identifiable information will be used
  • Information on how to withdraw from the study
  • Your rights as a volunteer

Visit Procedures

Procedures to measure efficacy and ensure the safety and well-being of all participants will be conducted throughout the trial by the study team. Some of these required procedures are listed below.

  • Medical and medication history
  • Vital signs
  • Measurement of body weight
  • Physical examinations
  • Blood and urine sample collections
  • Electrocardiogram (ECG)
  • Visual acuity and ocular tests

What to Expect During the Magnify Study

Informed Consent

To participate in the Magnify Study, participants will be asked to read and sign an Informed Consent Form (ICF). The form explains:

  • The purpose of the study

  • Required study visits and procedures
  • Potential risks and benefits of participation
  • Confidentiality

  • How participant identifiable information will be used

  • Information on how to withdraw from the study

Visit Procedures

Procedures to measure efficacy and ensure the safety and well-being of all participants will be conducted throughout the trial by the study team. Some of these required procedures are listed below.

  • Medical and medication history
  • Vital signs

  • Measurement of body weight

  • Physical examinations
  • Blood and urine sample collections
  • Electrocardiogram (ECG)
  • Visual acuity and ocular tests

Why Participate in the Study?

By participating in this study, you may not directly benefit but you could be an important part of finding new treatments for macular degeneration.

Why Participate in the Study?

By participating in this study, you may not directly benefit but you could be an important part of finding new treatments for macular degeneration.

What is Age-Related Macular Degeneration (AMD)?

Woman having eye exam

Age-related macular degeneration (AMD) is an eye disease that affects the central part of one’s vision. It is the most common form of irreversible blindness in the world. Approximately 25% of people over 80 years of age suffer from this condition, which affects approximately 11 million Americans.

There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more prevalent form of the disease, and is caused by a thinning of the macula, the central part of the retina. The retina is in the back of the eye and is made up of specialized neurons called photoreceptors, which are required for vision.

The gradual loss of central vision in dry AMD can present limitations to reading and driving, while peripheral vision (ability to see things off to the sides) is typically unaffected. The amount of vision loss depends on the location and extent of geographic atrophy, a lesion in the macula that is caused by the loss of the photoreceptors, which creates a blind spot in the field of vision.

What is Age-Related Macular Degeneration (AMD)?

Age-related macular degeneration (AMD) is an eye disease that affects the central part of one’s vision. It is the most common form of irreversible blindness in the world. Approximately 25% of people over 80 years of age suffer from this condition, which affects approximately 11 million Americans annually.

There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more prevalent form of the disease, and is caused by a thinning of the macula, the central part of the retina. The retina is in the back of the eye and is made up of specialized neurons called photoreceptors, which are required for vision.

The gradual loss of central vision in dry AMD can present limitations to reading and driving, while peripheral vision (ability to see things off to the sides) is typically unaffected. The amount of vision loss depends on the location and extent of geographic atrophy, a lesion in the macula that is caused by the loss of the photoreceptors, which creates a blind spot in the field of vision.

Who is Eligible to Participate in the Magnify Study?

You may qualify for the Magnify Study if you:

  • Are 50 years of age or older

  • Have a diagnosis of geographic atrophy (GA) secondary to dry AMD in at least one eye

  • Women of child-bearing potential will be monitored by monthly pregnancy tests

  • Males with female partners of child-bearing potential must agree to abstinence or to use highly effective contraception with their partner

Note: There are additional criteria to qualify for the Magnify Study. A study site can help determine if someone qualifies by further pre-screening.

Who is Eligible to Participate in the Magnify Study?

You may qualify for the Magnify Study if you:

  • Are 50 years of age or older
  • Have a diagnosis of geographic atrophy (GA) of the macula secondary to dry AMD in at least one eye
  • Women of child-bearing potential will be monitored by monthly pregnancy tests
  • Males with female partners of child-bearing potential must agree to abstinence or to use highly effective contraception with their partner

Note: There are additional criteria to qualify for the Magnify Study. A study site can help determine if someone qualifies by further pre-screening.

Frequently Asked Questions

An investigational drug is not yet approved for sale or for use or by prescription from doctors for the condition being studied. Clinical research studies (or trials) are used to test the safety and effectiveness of an investigational drug.

A research study is designed to evaluate whether a study drug is safe and effective for use in humans. Every study drug goes through the research study process. Participants are given specific medical treatments and researchers closely monitor the results to help determine if the study drug should be approved for wider use. Participants play a very important role in advancing medicine for present and future generations.

A placebo is often similar in appearance to the study drug but does not contain any active ingredients. In this study, the placebo does not contain active ingredients and will be identical in appearance to the study drug capsule

A Screening Period of up to 28 days will determine if a person is eligible for the Magnify study. Eligible participants will enter a Treatment Period that is 24 months long. There is one final visit 1 month after the participant stops taking the study drug or placebo.

To help ensure that a research study is ethical and that participants’ rights are protected, Institutional Review Boards (IRB) and the U.S. Food and Drug Administration (FDA), review and approve study protocols that detail all aspects of how the study is conducted. There are also teams that monitor the study called Clinical Research Associates; they visit the study sites to ensure the study protocol procedures, research requirements, and country regulations are being followed throughout the study. Health authorities may also inspect the study sites to ensure the safety and rights of the participants in a study and the integrity of the research study goals.

There are security measures to protect personal information. This is to avoid personal information from being lost, used, altered, disclosed, or accessed in any unauthorized way. To protect the identity of the participant, personal study information will be coded (e.g., unique study numbers are assigned to each participant). More information about privacy maintenance will be shared with those who choose to participate in the study.

Study-related therapies and assessments will be provided at no cost. Participants will not be paid to take part in this study; however, study-related expenses, such as travel and time, may be reimbursed.

Participation in this study is voluntary. You can decide to stop at any time and may still be treated at the facility. The decision whether to take part in the study will not affect your current or future care at the facility.

Tell your study doctor if you are thinking about stopping or decide to stop. You should talk to the study doctor about leaving the study before the decision is made so that he/she can find out if you are having any side effects from study treatment and can explain how to stop safely.

You are asked to follow, without exception, the rules and instructions listed within the Informed Consent for the study. If you do not follow these rules and instructions, you may be withdrawn from the study.

In order to provide maximum protection for your health, the study will be under the direct supervision of the study doctor and will be conducted by trained personnel. You will need to provide all information about current and past health (medical history) at all study visits, including participation in any other research studies. This information is needed to protect your health.

If you have a primary care physician, it is strongly recommended that you inform him/her of your interest to participate in this research study.

More information about this research study can be found by visiting: ClinicalTrials.gov (NCT05893537)

Frequently Asked Questions

An investigational drug is not yet approved for sale or for use or by prescription from doctors for the condition being studied. Clinical research studies (or trials) are used to test the safety and effectiveness of an investigational drug.

A research study is designed to evaluate whether a study drug is safe and effective for use in humans. Every study drug goes through the research study process. Participants are given specific medical treatments and researchers closely monitor the results to help determine if the study drug should be approved for wider use. Participants play a very important role in advancing medicine for present and future generations.

A placebo is often similar in appearance to the study drug but does not contain any active ingredients. In this study, the placebo does not contain active ingredients and will be identical in appearance to the study drug capsule.

A Screening Period of up to 28 days will determine if a person is eligible for the Magnify study. Eligible participants will enter a Treatment Period that is 24 months long. There is one final visit 1 month after the participant stops taking the study drug or placebo.

To help ensure that a research study is ethical and that participants’ rights are protected, Institutional Review Boards (IRB) and the U.S. Food and Drug Administration (FDA), review and approve study protocols that detail all aspects of how the study is conducted. There are also teams that monitor the study called Clinical Research Associates; they visit the study sites to ensure the study protocol procedures, research requirements, and country regulations are being followed throughout the study. Health authorities may also inspect the study sites to ensure the safety and rights of the participants in a study and the integrity of the research study goals

There are security measures to protect personal information. This is to avoid personal information from being lost, used, altered, disclosed, or accessed in any unauthorized way. To protect the identity of the participant, personal study information will be coded (e.g., unique study numbers are assigned to each participant). More information about privacy maintenance will be shared with those who choose to participate in the study

Study-related therapies and assessments will be provided at no cost. Participants will not be paid to take part in this study; however, study-related expenses, such as travel and time, may be reimbursed.

Participation in this study is voluntary. You can decide to stop at any time and may still be treated at the facility. The decision whether to take part in the study will not affect your current or future care at the facility.

Tell your study doctor if you are thinking about stopping or decide to stop. You should talk to the study doctor about leaving the study before the decision is made so that he/she can find out if you are having any side effects from study treatment and can explain how to stop safely.

You are asked to follow, without exception, the rules and instructions listed within the Informed Consent for the study. If you do not follow these rules and instructions, you may be withdrawn from the study.

In order to provide maximum protection for your health, the study will be under the direct supervision of the study doctor and will be conducted by trained personnel. You will need to provide all information about current and past health (medical history) at all study visits, including participation in any other research studies. This information is needed to protect your health.

If you have a primary care physician, it is strongly recommended that you inform him/her of your interest to participate in this research study

More information about this research study can be found by visiting: ClinicalTrials.gov (NCT05893537)

Study Locations

Current study locations are listed below and more may be added at any time.

Study Locations

Current study locations are listed below and more may be added at any time.

      Help spread awareness of the Magnify Study by sharing with others.

      To share this study information with others click here.

      Help spread awareness of the Magnify Study by sharing with others.

      To share this study information with others click here.